{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:53:48Z","timestamp":1790182428602,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Metahealth","award":["Metahealth"],"award-info":[{"award-number":["Metahealth"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Maple Syrup Urine Disease (MSUD) is a rare metabolic disorder requiring lifelong restriction of branched-chain amino acids (BCAAs), and targeted supplementation with valine and isoleucine to maintain metabolic stability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A prospective, open-label, observational study was conducted over 56 days in 5 paediatric patients mean age 8.8 years (range 3\u201314) with classical MSUD. In Phase 1 (Days 0\u201328), participants received the ready to use (RTU) liquid valine formulation, while continuing their usual powdered isoleucine supplement. In Phase 2 (Days 29\u201356), participants returned to powdered valine and changed to the ready to use RTU liquid isoleucine supplement. Weekly plasma BCAAs were monitored. Acceptability, gastrointestinal tolerance, adherence, and dietary intake were assessed through questionnaires and food diaries.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>RTU liquid valine and isoleucine supplements were well tolerated and accepted by all participants. Plasma leucine decreased when taking both liquid valine (mean leucine 253 \u00b5mol\/L) and isoleucine (mean leucine 219 \u00b5mol\/L) compared to baseline (mean leucine 356 \u00b5mol\/L). Required doses of valine and isoleucine decreased by 30% and 18%, respectively, suggesting improved adherence or enhanced efficacy. Palatability and ease of use were rated more favourably for the RTU products, with no adverse effects or adherence issues reported. Dietary intake remained stable throughout the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These preliminary findings suggest that RTU valine and isoleucine formulations may offer potential advantages in MSUD management, simplifying administration, and enhancing user satisfaction. While limited by sample size and short-term evaluation, their practicality and patient-centered design warrant further investigation in larger, more diverse populations to establish long-term efficacy and broader applicability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04223-7","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T10:27:06Z","timestamp":1775125626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Simplifying supplementation in MSUD: tolerance and acceptability of liquid valine and isoleucine supplements in maple syrup urine disease"],"prefix":"10.1186","volume":"21","author":[{"given":"Martina","family":"Tosi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2579-8699","authenticated-orcid":false,"given":"Anne","family":"Daly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Evans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ashmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"4223_CR1","doi-asserted-by":"publisher","unstructured":"Muelly ER, et al. Biochemical correlates of neuropsychiatric illness in maple syrup urine disease. J Clin Invest. Apr 2013;123(4):1809\u201320. https:\/\/doi.org\/10.1172\/JCI67217.","DOI":"10.1172\/JCI67217"},{"key":"4223_CR2","doi-asserted-by":"publisher","unstructured":"Strauss KA, Morton DH. Branched-chain ketoacyl dehydrogenase deficiency: maple syrup disease. Curr Treat Options Neurol. Jul 2003;5(4):329\u201341. https:\/\/doi.org\/10.1007\/s11940-003-0039-3.","DOI":"10.1007\/s11940-003-0039-3"},{"key":"4223_CR3","doi-asserted-by":"publisher","unstructured":"Zinnanti WJ, et al. Dual mechanism of brain injury and novel treatment strategy in maple syrup urine disease. Brain. 2009 Apr;132(Pt 4):903\u201318. https:\/\/doi.org\/10.1093\/brain\/awp024.","DOI":"10.1093\/brain\/awp024"},{"key":"4223_CR4","doi-asserted-by":"publisher","unstructured":"Homanics GE, Skvorak K, Ferguson C, Watkins S, Paul HS. Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med Genet. 2006 Mar 31;7:33. https:\/\/doi.org\/10.1186\/1471-2350-7-33.","DOI":"10.1186\/1471-2350-7-33"},{"key":"4223_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.2147\/TACG.S125962","volume":"10","author":"PR Blackburn","year":"2017","unstructured":"Blackburn PR, et al. Maple syrup urine disease: mechanisms and management. Appl Clin Genet. 2017;10:57\u201366. https:\/\/doi.org\/10.2147\/TACG.S125962.","journal-title":"Appl Clin Genet"},{"key":"4223_CR6","unstructured":"UKGovernment. Newborn blood spot screening: programme overview. https:\/\/www.gov.uk. (accessed."},{"key":"4223_CR7","doi-asserted-by":"publisher","unstructured":"Strauss KA, et al. Classical maple syrup urine disease and brain development: principles of management and formula design. Mol Genet Metab. 2010 Apr;99(4):333\u201345. https:\/\/doi.org\/10.1016\/j.ymgme.2009.12.007.","DOI":"10.1016\/j.ymgme.2009.12.007"},{"key":"4223_CR8","doi-asserted-by":"publisher","unstructured":"Strauss KA, et al. Branched-chain alpha-ketoacid dehydrogenase deficiency (maple syrup urine disease): treatment, biomarkers, and outcomes. Mol Genet Metab. Mar 2020;129(3):193\u2013206. https:\/\/doi.org\/10.1016\/j.ymgme.2020.01.006.","DOI":"10.1016\/j.ymgme.2020.01.006"},{"key":"4223_CR9","doi-asserted-by":"publisher","unstructured":"Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Diagnosis and treatment of maple syrup disease: a study of 36 patients. Pediatrics. Jun 2002;109(6):999\u20131008. https:\/\/doi.org\/10.1542\/peds.109.6.999.","DOI":"10.1542\/peds.109.6.999"},{"key":"4223_CR10","doi-asserted-by":"publisher","unstructured":"Frazier DM, et al. Nutrition management guideline for maple syrup urine disease: an evidence- and consensus-based approach. Mol Genet Metab. Jul 2014;112(3):210\u20137. https:\/\/doi.org\/10.1016\/j.ymgme.2014.05.006.","DOI":"10.1016\/j.ymgme.2014.05.006"},{"key":"4223_CR11","doi-asserted-by":"publisher","unstructured":"Alrige M, Banjar H, Shuaib T, Ahmed A, Gharbawi R. Knowledge-based dietary intake recommendations of nutrients for pediatric patients with maple syrup urine disease. Healthc (Basel). Jan 18 2023;11(3). https:\/\/doi.org\/10.3390\/healthcare11030301.","DOI":"10.3390\/healthcare11030301"},{"key":"4223_CR12","unstructured":"BIMDG. British Inherited Metabolic Disease Group UK Guidelines. (accessed."},{"key":"4223_CR13","doi-asserted-by":"publisher","unstructured":"van Vliet D, et al. Single amino acid supplementation in aminoacidopathies: a systematic review. Orphanet J Rare Dis. Jan 13 2014;9:7. https:\/\/doi.org\/10.1186\/1750-1172-9-7.","DOI":"10.1186\/1750-1172-9-7"},{"key":"4223_CR14","doi-asserted-by":"publisher","unstructured":"Ziadlou M, MacDonald A. Alternative sources of valine and isoleucine for prompt reduction of plasma leucine in maple syrup urine disease patients: A case series. JIMD Rep. Nov 2022;63(6):555\u201362. https:\/\/doi.org\/10.1002\/jmd2.12327.","DOI":"10.1002\/jmd2.12327"},{"key":"4223_CR15","doi-asserted-by":"publisher","unstructured":"Goyanes A, et al. Automated therapy Preparation of isoleucine formulations using 3D printing for the treatment of MSUD: first single-centre, prospective, crossover study in patients. Int J Pharm. Aug 15 2019;567:118497. https:\/\/doi.org\/10.1016\/j.ijpharm.2019.118497.","DOI":"10.1016\/j.ijpharm.2019.118497"},{"key":"4223_CR16","unstructured":"NHSGuidelines. Salt in your diet https:\/\/www.nhs.uk."},{"key":"4223_CR17","doi-asserted-by":"publisher","unstructured":"Ewing CB, et al. Metabolic control and ideal outcomes in liver transplantation for maple syrup urine disease. J Pediatr. Oct 2021;237:59\u201364 e1. https:\/\/doi.org\/10.1016\/j.jpeds.2021.06.028.","DOI":"10.1016\/j.jpeds.2021.06.028"},{"key":"4223_CR18","doi-asserted-by":"publisher","unstructured":"Kenneson A, Osara Y, Pringle T, Youngborg L, Singh RH. Natural history of children and adults with maple syrup urine disease in the NBS-MSUD connect registry. Mol Genet Metab Rep. Jun 2018;15:22\u20137. https:\/\/doi.org\/10.1016\/j.ymgmr.2018.01.001.","DOI":"10.1016\/j.ymgmr.2018.01.001"},{"key":"4223_CR19","doi-asserted-by":"publisher","unstructured":"Gokmen-Ozel H, Daly A, Davies P, Chahal S, MacDonald A. Errors in emergency feeds in inherited metabolic disorders: a randomised controlled trial of three Preparation methods. Arch Dis Child. Oct 2010;95(10):776\u201380. https:\/\/doi.org\/10.1136\/adc.2010.161711.","DOI":"10.1136\/adc.2010.161711"},{"key":"4223_CR20","doi-asserted-by":"publisher","unstructured":"Morel T, Ayme S, Cassiman D, Simoens S, Morgan M, Vandebroek M. Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers. Orphanet J Rare Dis. May 26 2016;11(1):70. https:\/\/doi.org\/10.1186\/s13023-016-0444-9.","DOI":"10.1186\/s13023-016-0444-9"},{"key":"4223_CR21","doi-asserted-by":"publisher","unstructured":"Burrage LC, Jain M, Gandolfo L, Lee BH, C. Members of the Urea Cycle Disorders, Nagamani SC. Sodium phenylbutyrate decreases plasma branched-chain amino acids in patients with urea cycle disorders. Mol Genet Metab. Sep-Oct 2014;113(1\u20132):131\u20135. https:\/\/doi.org\/10.1016\/j.ymgme.2014.06.005.","DOI":"10.1016\/j.ymgme.2014.06.005"},{"issue":"no Suppl 1","key":"4223_CR22","doi-asserted-by":"publisher","first-page":"S72","DOI":"10.1016\/j.ymgme.2010.02.019","volume":"100 Suppl 1","author":"F Scaglia","year":"2010","unstructured":"Scaglia F. New insights in nutritional management and amino acid supplementation in Urea cycle disorders. Mol Genet Metab. 2010;100 Suppl 1(no Suppl 1):S72\u20136. https:\/\/doi.org\/10.1016\/j.ymgme.2010.02.019.","journal-title":"Mol Genet Metab"},{"key":"4223_CR23","doi-asserted-by":"publisher","unstructured":"Manoli I, Myles JG, Sloan JL, Shchelochkov OA, Venditti CP. A critical reappraisal of dietary practices in methylmalonic acidemia raises concerns about the safety of medical foods. Part 1: isolated methylmalonic acidemias. Genet Med. Aug 2015;13. https:\/\/doi.org\/10.1038\/gim.2015.102.","DOI":"10.1038\/gim.2015.102"},{"key":"4223_CR24","doi-asserted-by":"publisher","unstructured":"Myles JG, Manoli I, Venditti CP. Effects of medical food leucine content in the management of methylmalonic and propionic acidemias. Curr Opin Clin Nutr Metab Care. Jan 2018;21(1):42\u20138. https:\/\/doi.org\/10.1097\/MCO.0000000000000428.","DOI":"10.1097\/MCO.0000000000000428"},{"key":"4223_CR25","doi-asserted-by":"publisher","unstructured":"Tabanlioglu D, Ersoy-Evans S, Karaduman A. Acrodermatitis enteropathica-like eruption in metabolic disorders: acrodermatitis dysmetabolica is proposed as a better term. Pediatr Dermatol. Mar-Apr 2009;26(2):150\u20134. https:\/\/doi.org\/10.1111\/j.1525-1470.2008.00803.x.","DOI":"10.1111\/j.1525-1470.2008.00803.x"},{"key":"4223_CR26","doi-asserted-by":"publisher","unstructured":"Touati G, et al. Methylmalonic and propionic acidurias: management without or with a few supplements of specific amino acid mixture. J Inherit Metab Dis. Apr-Jun 2006;29(2\u20133):288\u201398. https:\/\/doi.org\/10.1007\/s10545-006-0351-7.","DOI":"10.1007\/s10545-006-0351-7"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04223-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04223-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:24:34Z","timestamp":1781645074000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04223-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4223"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04223-7","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"27 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Institutional review board statement: The study \u2018Valine 50 mg\/mL and isoleucine 25 mg\/mL oral solutions for Maple Syrup Urine Disease (MSUD) \u2013 Acceptability and Tolerance Study\u2019 was given favourable ethical approval by the West Midland, South Birmingham Research Ethical Committee (REC reference, 24\/WM\/0171; IRAS project ID, 324480; ClinicalTrials.gov ID NCT06581991 date 3\/9\/2024). The study was conducted in adherence with the guidelines of the Local Ethical Committee and in accordance with the ethical standards of the 2024 Helsinki Declaration. Written informed consent and assent for the use of anonymized data was obtained from each participant\u2019s parent or legal guardian.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Informed Consent Statement: Informed consent was obtained from all subjects involved in the study for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Anita MacDonald has received research or advisory board funding from Biomarin, PTC Therapeutics, Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients, Jnana Therapeutics, PIAM, Ipsen Pharma and Galen. Anne Daly Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Sharon Evans Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Alex Pinto Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Catherine Ashmore Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Martina Tosi has no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"124"}}